Form 4: BioCardia Director Blank Buys 288,000 Shares & Warrants

BioCardia Director Andrew Scott Blank acquired 288,000 shares of common stock and an equal number of warrants at $1.25 per unit, increasing his indirect beneficial ownership.

Summary

• Director Andrew Scott Blank purchased securities of BioCardia, Inc. (BCDA).
• The transaction occurred on September 19, 2025.
• Blank acquired 288,000 shares of BioCardia, Inc. common stock.
• He also acquired 288,000 warrants, each exercisable to purchase one share of common stock.
• The purchase price was $1.25 per unit, which included one share of common stock and one warrant.
• The warrants have an exercise price of $1.25 and are set to expire on September 20, 2027.
• Following this transaction, Blank indirectly beneficially owns 634,023 shares of common stock and 602,522 warrants.
• These securities are held by the Andy Blank Revocable Living Trust, for which Blank serves as trustee.

Sentiment

Score: 8

Explanation: A director's significant purchase of common stock and warrants indicates strong confidence in the company's future performance and valuation, which is generally a positive signal for investors.

Positives

• Director Andrew Scott Blank significantly increased his stake in BioCardia, Inc. through the purchase of 288,000 shares and 288,000 warrants.
• Insider buying, particularly from a director, often signals strong confidence in the company's future prospects and current valuation.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Director Andrew Scott Blank, a related party, acquired 288,000 shares of common stock and 288,000 warrants directly from BioCardia, Inc.

Stakeholder Impact

• Shareholders may view the director's substantial purchase as a positive signal of confidence in the company's prospects, potentially influencing stock price positively.
• The company benefits from the capital infusion of $360,000 from the direct sale of securities to the director.

Key Dates

Recommendation

Director Andrew Scott Blank's substantial purchase of BioCardia common stock and warrants at $1.25 per unit signals strong conviction in the company's future prospects and current valuation. Insider buying, especially from a director, is often interpreted as a bullish indicator, suggesting that those closest to the company believe the stock is undervalued or poised for growth. This action could inspire investor confidence and warrants a 'buy' recommendation.

Keywords

BioCardia, BCDA, Andrew Scott Blank, insider transaction, Form 4, stock purchase, warrants, director, equity acquisition